Breaking barriers: NEK2 inhibition shines in multiple myeloma treatment.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 37852178.
- Also identified by DOI 10.1016/j.xcrm.2023.101237 and PMC identifier 10591060.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In their article, Cheng et al.<sup>1</sup> reveal that NEK2 loss reshapes the tumor microenvironment, reducing tumor-associated macrophages and decreasing T cell exhaustion. They show that this ultimately favors the immune system's anti-cancer response in multiple myeloma.
Medical subject headings
- Multiple Myeloma